Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story
Raul Montiel-Esparza
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Palo Alto, California, USA
Search for more papers by this authorSuzanne M. Michalak
Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorAnthony Huy Dinh Le
University of Missouri - Kansas City School of Medicine, Kansas City, Missouri, USA
Search for more papers by this authorChristopher Or
Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorQuan Dong Nguyen
Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorRuby Khoury
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
Search for more papers by this authorMichael S. Grimley
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
Search for more papers by this authorAlice Bertaina
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Palo Alto, California, USA
Search for more papers by this authorEdna Klinger
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Palo Alto, California, USA
Search for more papers by this authorCorresponding Author
Ami J. Shah
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Palo Alto, California, USA
Correspondence
Ami J. Shah, 1000 Welch Rd, Suite 300, Palo Alto, CA, 94304, USA
Email: [email protected]
Search for more papers by this authorEdward H. Wood
Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorRaul Montiel-Esparza
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Palo Alto, California, USA
Search for more papers by this authorSuzanne M. Michalak
Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorAnthony Huy Dinh Le
University of Missouri - Kansas City School of Medicine, Kansas City, Missouri, USA
Search for more papers by this authorChristopher Or
Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorQuan Dong Nguyen
Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorRuby Khoury
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
Search for more papers by this authorMichael S. Grimley
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
Search for more papers by this authorAlice Bertaina
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Palo Alto, California, USA
Search for more papers by this authorEdna Klinger
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Palo Alto, California, USA
Search for more papers by this authorCorresponding Author
Ami J. Shah
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Palo Alto, California, USA
Correspondence
Ami J. Shah, 1000 Welch Rd, Suite 300, Palo Alto, CA, 94304, USA
Email: [email protected]
Search for more papers by this authorEdward H. Wood
Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorRaul Montiel-Esparza and Suzanne M. Michalak are the co-first authors.
Ami J. Shah and Edward H. Wood are the co-senior authors.
Abstract
Cytomegalovirus retinitis (CMVR) following hematopoietic stem cell transplantation (HCT) for a primary immunodeficiency is a rare but highly morbid condition with potential irreversible consequences despite optimal antiviral pharmacotherapy. Viral-specific T cells (VSTs) pose a promising and safe approach eradicating intractable viral disease. We describe the case of a 21-month-old male with Wiskott–Aldrich syndrome (WAS) and CMVR post HCT with sustained long-term virologic and clinical response after CMV-specific T-cell therapy. This case highlights the need to consider VST as an adjunct upfront strategy in refractory CMVR and for routine ophthalmologic screening and surveillance in high-risk patients post HCT.
CONFLICT OF INTEREST STATEMENT
The authors declare they have no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019; 7: 295. doi:10.3389/fped.2019.00295
- 2Zając-Spychała O, Zaucha-Prażmo A, Zawitkowska J, et al. Infectious complications after hematopoietic stem cell transplantation for primary immunodeficiency in children: a multicenter nationwide study. Pediatr Allergy Immunol. 2020; 31(5): 537-543. doi:10.1111/pai.13239
- 3Prockop SE, Hasan A, Koehne G, et al. Third party donor derived CMV specific T cells for the treatment of refractory CMV viremia and disease after hematopoietic stem cell transplant. Blood. 2014; 124(21): 184-184. doi:10.1182/blood.V124.21.184.184
- 4Vassallo F, Nuzzi R, Cattani I, et al. CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins. Ther Adv Hematol. 2020; 11:204062072097565. doi:10.1177/2040620720975651
- 5Mori T, Kikuchi T, Koh M, et al. Cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation under Cytomegalovirus antigenemia-guided active screening. Bone Marrow Transplant. 2021; 56(6): 1266-1271. doi:10.1038/s41409-020-01176-8
- 6Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of Cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001; 32(2): 214-219. doi:10.1086/318447
- 7Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory Cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010; 116(20): 4360-4367. doi:10.1182/blood-2010-01-262089
- 8Qian C, Wang Y, Reppel L, et al. Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT. Bone Marrow Transplant. 2018; 53(2): 114-122. doi:10.1038/bmt.2017.232
- 9Gupta MP, Koenig LR, Doubrovina E, et al. Ocular outcomes after treatment of Cytomegalovirus retinitis using adoptive immunotherapy with Cytomegalovirus-specific cytotoxic T lymphocytes. Ophthalmol Retina. 2021; 5(9): 838-849. doi:10.1016/j.oret.2021.04.009
- 10Seo S, Smith C, Fraser C, et al. Adoptive T-cell therapy for pediatric Cytomegalovirus-associated retinitis. Blood Adv. 2019; 3(11): 1774-1777. doi:10.1182/bloodadvances.2019000121
- 11Sepah YJ, Do DV, Nguyen QD. Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017; 183: 71-80.
- 12Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of Cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001; 97(5): 1232-1240. doi:10.1182/blood.v97.5.1232
- 13Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15: 1143-1238.
- 14Henon PR, Liang H, Beck-Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant. 1992; 9: 285-291.
- 15Talmadge JE, Reed E, Ino K, et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 1997; 19: 161-172.
- 16Komanduri KV, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007; 110: 4543-4551.
- 17Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood. 1996; 87: 3984-3992.
- 18Orellana J, Teich SA, Winterkorn JS, et al. Treatment of Cytomegalovirus retinitis with ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (BW B759U). Br J Ophthalmol. 1988; 72(7): 525-529. doi:10.1136/bjo.72.7.525
- 19Nelson AS, Heyenbruch D, Rubinstein JD, et al. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Adv. 2020; 4(22): 5745-5754. doi:10.1182/bloodadvances.2020003073
- 20Bollard CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016; 127(26): 3331-3340. doi:10.1182/blood-2016-01-628982
- 21Houghtelin A, Bollard CM. Virus-specific T cells for the immunocompromised patient. Front Immunol. 2017; 8: 1272. doi:10.3389/fimmu.2017.01272
- 22Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye Lond Engl. 2013; 27(7): 787-794. doi:10.1038/eye.2013.107
